MedTrace Logo

Oral Iron Supplementation for Patients With Chronic Kidney Disease

NCT05544513 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-04-03

No results posted yet for this study

Summary

The hypothesis of this research is that oral iron prescribed in a single dose in alternate day could mitigate the side effects with regard to intestinal microbiota, inflammation, oxidative stress and improve the hematological profile when compared to daily oral iron prescription

Conditions

  • Chronic Renal Disease
  • Iron-Deficiency Anemia
  • Anemia of Chronic Kidney Disease
  • Dysbiosis

Interventions

DRUG

Ferrous sulfate 3 days week

Participants will receive one ferrous sulfate capsule (120 mg of elemental iron) on Mondays, Wednesdays and Fridays

DRUG

Ferrous sulfate daily

Participants will receive one ferrous sulfate (120 mg of elemental iron) capsule daily (except on Sundays)

DRUG

Ferrous sulfate higher concentration

Participants will receive one ferrous sulfate capsule (240mg of elemental iron) on Mondays, Wednesdays and fridays

Sponsors & Collaborators

  • Universidade Federal Fluminense

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2026-12-29
Completion
2026-12-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05544513 on ClinicalTrials.gov